Literature DB >> 769481

Studies of Escherichia coli O antigen specific antibodies in human milk, maternal serum and cord blood.

B Carlsson, L Gothefors, S Ahlstedt, L A Hanson, J Winberg.   

Abstract

Studies of Escherichia coli O antigen specific antibodies in human milk, maternal serum and cord blood. Acta Paediatr Scand, 65:216, 1976.--The quantity and class specificity of E. coli O antibodies in human milk, maternal serum and cord blood was determined by the enzyme-linked immunosorbent assay. The predominant Ig-class of these antibodies in milk was IgA. The initially high levels of antibodies decreased 10-fold during the first days, but there seemed to be a fairly constant daily production of IgA antibodies during the first two months of the nursing period. There was no obvious decline in antibody content from morning to night or during a meal. The ratio milk antibody/serum antibody was very high for IgA, suggesting a local production. The ratios for the IgG were all less than 1, suggesting a restricted transfer from the serum. Ratios around 1 for IgM did not exclude some local production. In umbilical cord serum the amount of IgG E. coli O antibodies was higher than that in maternal serum. Small amounts of IgM and IgA antibodies was also demonstrated in some cases. In milk as well as in serum there were antibodies against a wide variety of E. coli O groups, not only to the actual E. coli strain dominating the mother's gut flora.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 769481     DOI: 10.1111/j.1651-2227.1976.tb16541.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  13 in total

1.  Production of cytotoxic necrotizing factor, verocytotoxin and haemolysin by pyelonephritogenic Escherichia coli.

Authors:  A Brauner; M Katouli; K Tullus; S H Jacobson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

2.  Escherichia coli populations from diabetic and non-diabetic patients with bacteraemia and faecal samples from healthy subjects--a comparative study.

Authors:  A Brauner; B Hylander; B Wretlind; C G Ostenson; I Kühn
Journal:  Epidemiol Infect       Date:  1990-12       Impact factor: 2.451

3.  Naturally occurring antibodies in human sera that react with the iron-regulated outer membrane proteins of Escherichia coli.

Authors:  E Griffiths; P Stevenson; R Thorpe; H Chart
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

4.  Cell surface hydrophobicity, adherence to HeLa cell cultures and haemagglutination pattern of pyelonephritogenic Escherichia coli strains.

Authors:  A Brauner; M Katouli; K Tullus; S H Jacobson
Journal:  Epidemiol Infect       Date:  1990-10       Impact factor: 2.451

5.  Amoxicillin promotes vaginal colonization with adhering Escherichia coli present in faeces.

Authors:  M Herthelius; R Möllby; C E Nord; J Winberg
Journal:  Pediatr Nephrol       Date:  1989-10       Impact factor: 3.714

6.  Human colostral cells. I. Separation and characterization.

Authors:  S S Crago; S J Prince; T G Pretlow; J R McGhee; J Mestecky
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

7.  The importance of P and type 1 fimbriae for the persistence of Escherichia coli in the human gut.

Authors:  K Tullus; I Kühn; I Orskov; F Orskov; R Möllby
Journal:  Epidemiol Infect       Date:  1992-06       Impact factor: 2.451

Review 8.  Esch. coli infections in childhood. Significance of bacterial virulence and immune defence.

Authors:  L A Hanson
Journal:  Arch Dis Child       Date:  1976-10       Impact factor: 3.791

9.  Epidemiological aspects of fecal colonization with P-fimbriated Escherichia coli in neonates.

Authors:  K Tullus; M Kalin; R Möllby; A Olin; S B Svenson; G Källenius
Journal:  Infection       Date:  1987 Jan-Feb       Impact factor: 3.553

10.  Colonization and persistence of Escherichia coli phenotypes in the intestines of children aged 0 to 18 months.

Authors:  I Kühn; K Tullus; R Möllby
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.